A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CINV / chemotherapy-induced nausea and vomiting

[Related PubMed/MEDLINE]
Total Number of Papers: 868
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CINV  (>> Co-occurring Abbreviation)
Long Form:   chemotherapy-induced nausea and vomiting
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. CAPOX, CC, CR, MEC, PTX, TC
2020 A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. CR, FOS, ISR
2020 A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin. ---
2020 A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting. HEC, MEC, RA
2020 A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan. CR, DEX, HEC, NK1RA
2020 A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. ---
2020 A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. ---
2020 Acupuncture therapy for preventing the nausea and vomiting following high emetic risk chemotherapy: A protocol for systematic review and Bayesian Network meta-analysis. MRC, NMA, UMCG
2020 Acupuncture treatment for chemotherapy-induced nausea and vomiting: A protocol for systematic review and meta-analysis. CBM, CNKI, RevMan
10  2020 Adherence to ASCO for Prophylaxis of Acute Chemotherapy- Induced Nausea and Vomiting in Iran. ASCO
11  2020 Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy. CR
12  2020 Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. ESMO, GITMO, HSCT, MASCC, NK1RA
13  2020 Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. allo-HSCT, FG, MEC or HEC
14  2020 Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis. CIs, ORs
15  2020 Capsule-related dysphagia and the use of netupitant/palonosetron (Akynzeo™) capsules - A report of two cases and a solution. ---
16  2020 Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study. CIN, CIV
17  2020 Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. HEC, MEC, VAS
18  2020 Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia. MBC, ORR, PFS
19  2020 Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center. ---
20  2020 Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. HEC, NEPA, NEPA, NK1RA, PSA, QALDs, US
21  2020 Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data. DEX, HEC, MEC, NEPA, PALO
22  2020 Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data. DEX, HEC, MEC, NEPA, PALO
23  2020 Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine. QOL
24  2020 Design of a zero-order sustained release PLGA microspheres for palonosetron hydrochloride with high encapsulation efficiency. EE, Pal-MS
25  2020 Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting - A systematic review and meta-analysis. ---
26  2020 Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India. CR, HEC/MEC, NEPA
27  2020 Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. 5HT3-RAs, ASCT, CT, HD, MD, NK1RAs
28  2020 Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting. AEs, QOL, RCTs, RR, THD
29  2020 Efficacy of acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: a multi-center, single-blind, randomized, sham-controlled clinical research. CTCAE, ECOG, HADS, SA, SNAQ, TA
30  2020 Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. APR/GRAN, HEC
31  2020 Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis. CR, HEC, NK-1-RA, OR, PALO-DEX, RNN, SUCRA
32  2020 Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study. 5-HT3 RA, CC, CR, FLIE, MEC, QOL
33  2020 Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran. ---
34  2020 Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center. HSRs
35  2020 Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese". AML, CR, TTF
36  2020 Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective. QOL
37  2020 Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting. ---
38  2020 Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial. AP, CR, DP, NK-1, OP, RAs
39  2020 Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety. CY, GTDS
40  2020 Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA). 5-HT3RA, AC, NEPA, NK1-RA
41  2020 Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial. DEX, MCP arm, MEC, TC
42  2020 Music interventions for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. CBM, CENTRAL, CINAHL, CNKI, RCTs
43  2020 Nanotechnology based blended chitosan-pectin hybrid for safe and efficient consolidative antiemetic and neuro-protective effect of meclizine hydrochloride in chemotherapy induced emesis. ---
44  2020 Nausea and vomiting during post-transplantation cyclophosphamide administration. 5-HT3 RA, CY/TBI, NK1-RA, PTCy
45  2020 Nausea in Numbers: Electronic Medical Record Nausea and Vomiting Assessment for Children With Cancer. BARF
46  2020 NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience. CR, NSCLC
47  2020 NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. neo
48  2020 Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. AC, CR, NEPA
49  2020 Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. 5-HT3 RA, AEs, CBM, CNKI, RCTs
50  2020 Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial. CR, HEC
51  2020 Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. CI, OR, RCTs
52  2020 Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. FLIE
53  2020 Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review. ---
54  2020 Patient-related Risk Factors for Nausea and Vomiting With Standard Antiemetics in Patients With Cancer Receiving Carboplatin: A Retrospective Study. CR
55  2020 Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. CI, OR
56  2020 Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. AC, AE, NK-1, RA
57  2020 Prevention of chemotherapy-induced nausea and vomiting with acupuncture: A protocol for systematic review and meta-analysis. ---
58  2020 Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. HR, NOGGO
59  2020 Psychometric assessment of the Persian version of short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemetic tool. EFA, INVR, MASCC, MAT
60  2020 Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. CC, CR, QOL
61  2020 Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. AE, APR, CR, HEC
62  2020 Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide". ---
63  2020 Revisiting the physiology of nausea and vomiting-challenging the paradigm. ---
64  2020 Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301). BMI, CC, CI, CR, MEC, OR
65  2020 RNA-Seq reveals inflammatory mechanisms of Xiao-Ban-Xia-Tang decoction to ameliorate cisplatin-induced emesis in a rat pica model. DEGs, XBXT
66  2020 Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience. ---
67  2020 Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. MEC, RA, TEAEs
68  2020 Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type. AC, CR, GI, HEC and MEC
69  2020 The Antiemetic Effect of Xiao-Ban-Xia-Tang Formula against Cisplatin-Induced Emesis is Mediated through Inhibition of NLRP3 Inflammasome Activation in a Rat Pica Model. HE, ROS, XBXT
70  2020 The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. CR, HEC
71  2020 Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis. CI, OR, RR
72  2020 Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. ---
73  2020 What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. AC, CV, HEC, NK1RA
74  2019 A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan. CR, DEX, HEC, NK1RA
75  2019 A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. NK-1
76  2019 A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study. KSWOG, MEC, QOL
77  2019 A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. auto-SCT, PAL
78  2019 Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. AGA, CGA, HEC, MEC
79  2019 Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. CR
80  2019 An investigation into the effect of gabapentin capsules on the reduction of nausea and vomiting after chemotherapy in cancerous patients under platinum-based treatment. ---
81  2019 Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database. ---
82  2019 Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center. ---
83  2019 ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. ---
84  2019 Auriculotherapy to control chemotherapy-induced nausea and vomiting in patients with cancer: protocol of a systematic review. GRADE, PRISMA-P, RCTs
85  2019 Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting. HEC, MEC, NEPA, NK-1, RAs
86  2019 Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. HEC
87  2019 Chemotherapy-induced nausea and vomiting from oral chemotherapy for childhood acute lymphoblastic leukaemia: feasibility study. ALL
88  2019 Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial. AUC, CR, DEX, GRN, NK1RA, OLZ
89  2019 Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study. CR
90  2019 Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy. ---
91  2019 Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. HEC, ICER, QALY, SEA
92  2019 Cost-utility analysis of aprepitant for patients who truly need it in Japan. ICER, NK1RA, QALY
93  2019 Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy. MEC, RA, TEAEs
94  2019 Dexamethasone-sparing regimen is an effective and safe alternative in overall antiemetic protection: A systematic review and meta-analysis. CI, RR
95  2019 Does the Oral Administration of Ginger Reduce Chemotherapy-Induced Nausea and Vomiting?: A Meta-analysis of 10 Randomized Controlled Trials. CI, OR
96  2019 Effect of acupoint therapies on chemotherapy-induced nausea and vomiting: A systematic review protocol. CBM, CNKI, MD, RR, SMD
97  2019 Effect of electrical stimulation for chemotherapy-induced nausea and vomiting in patients with liver cancer. ES, LC
98  2019 Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. CR, DEX, NEPA, OLZ, OR, PAL, PAL0.75
99  2019 Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies. ---
100  2019 Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. ---